Pharmacokinetic-pharmacodynamic target attainment analysis of cefozopran in Japanese adult patients

Journal of Infection and Chemotherapy

Volumn 14, Issue 2, 2008, Pages 130-136

  Ikawa, Kazuro ^a   Nomura, Kenichi ^b   Morikawa, Norifumi ^a   Ikeda, Kayo ^a   Ohge, Hiroki ^a   Sueda, Taijiro ^a   Taniwaki, Masafumi ^b  

^a HIROSHIMA UNIVERSITY   (Japan)

^b KYOTO PREFECTURAL UNIVERSITY OF MEDICINE   (Japan)

Author keywords

Cefozopran; Dosing regimen; Monte Carlo simulation; Pharmacodynamics; Pharmacokinetics

Indexed keywords

CEFOZOPRAN; CREATININE;

ADULT; AGED; ARTICLE; BACTERIUM ISOLATE; BODY WEIGHT; CLINICAL ARTICLE; CREATININE CLEARANCE; ESCHERICHIA COLI; FEMALE; HUMAN; KLEBSIELLA PNEUMONIAE; MALE; MINIMUM INHIBITORY CONCENTRATION; MONTE CARLO METHOD; PHARMACODYNAMICS; PSEUDOMONAS AERUGINOSA; STREPTOCOCCUS PNEUMONIAE;

EID: 43049103092     PISSN: 1341321X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10156-008-0589-0     Document Type: Article

References (25)

1. H. Kobayashi S. Moritono K. Hara Significant role of new cephem antibiotics: focused on cefozopran Jpn J Antibiot 50 1997 807 820
2. G.L. Drusano S.L. Preston C. Hardalo R. Hare C. Banfield D. Andes Use of preclinical data for selection of a phase II/III dose for evernimicin and identification of a preclinical MIC breakpoint Antimicrob Agents Chemother 45 2001 13 22 10.1128/AAC.45.1.13-22.2001
3. V.H. Tam A. Louie B.M. Lomaestro G.L. Drusano Integration of population pharmacokinetics, a pharmacodynamic target, and microbiologic surveillance data to generate a rational empiric dosing strategy for cefepime against Pseudomonas aeruginosa Pharmacotherapy 23 2003 291 295 10.1592/phco.23.3.291.32110
4. E. Ludwig M. Konkoly-Thege J.L. Kuti D.P. Nicolau Optimising antibiotic dosing regimens based on pharmacodynamic target attainment against Pseudomonas aeruginosa collected in Hungarian hospitals Int J Antimicrob Agents 28 2006 433 438 10.1016/j.ijantimicag.2006.07.014
5. K.J. Eagye J.L. Kuti M. Dowzicky D.P. Nicolau Empiric therapy for secondary peritonitis: a pharmacodynamic analysis of cefepime, ceftazidime, ceftriaxone, imipenem, levofloxacin, piperacillin/tazobactam, and tigecycline using Monte Carlo simulation Clin Ther 29 2007 889 899 10.1016/j.clinthera.2007.05.018
6. W. Paulfeuerborn H.J. Muller K. Borner P. Koeppe H. Lode Comparative pharmacokinetics and serum bactericidal activities of SCE-2787 and ceftazidime Antimicrob Agents Chemother 37 1993 1835 1841
7. T. Yamamoto Y. Adachi Y. Nagamine M. Suwa T. Nanno Clinical phase I study of cefozopran Shinryou To Shinyaku (Treat New Med) 30 1993 281 304
8. Y. Higashiyama Y. Yamashita K. Mitsutake H. Matsuda Y. Miyazaki K. Tanaka Laboratory and clinical studies on cefozopran Jpn J Chemother 41 1993 233 244
9. Y. Katayama Y. Yamashita H. Kumon S. Kaku Transfer of cefozopran into the prostate tissues Jpn J Chemother 41 1993 158 163
10. H. Tanimura T. Nakai K. Takifuji T. Shimomura T. Okamura K. Ono Pharmacokinetics and clinical effect of cefozopran in surgical infections Jpn J Chemother 41 1993 373 383
11. A. Yafune H. Naito M. Takebe Population pharmacokinetic approach with Monte Carlo integration for clinical phase I trial of pilocarpine HCl tablet Jpn J Clin Pharmacol Ther 30 1999 423 433
12. W.A. Craig Interrelationship between pharmacokinetics and pharmacodynamics in determining dosage regimens for broad-spectrum cephalosporins Diagn Microbiol Infect Dis 22 1995 89 96 10.1016/0732-8893(95)00053-D
13. D.S. Burgess C.R. Frei Comparison of beta-lactam regimens for the treatment of gram-negative pulmonary infections in the intensive care unit based on pharmacokinetics/pharmacodynamics J Antimicrob Chemother 56 2005 893 898 10.1093/jac/dki335
14. K. Nomura N. Morikawa K. Ikawa K. Ikeda Y. Fujimoto D. Shimizu Optimized dosage and frequency of cefozopran for patients with febrile neutropenia based on population pharmacokinetic and pharmacodynamic analysis J Antimicrob Chemother 2008 doi:10.1093/jac/dkn038
15. K. Ikawa N. Morikawa S. Matsuda K. Ikeda H. Ohge T. Sueda Peritoneal penetration and pharmacodynamic exposure of intravenous cefozopran in abdominal surgery patients Int J Antimicrob Agents 30 2007 352 355 10.1016/j.ijantimicag.2007.06.001
16. K. Ikeda N. Morikawa M. Kuribayashi K. Ikawa K. Nomura M. Taniwaki Real-time therapeutic drug monitoring of cefozopran in plasma using high-performance liquid chromatography with ultraviolet detection J Pharm Biomed Anal 45 2007 811 816 10.1016/j.jpba.2007.08.004
17. K. Yamaguchi Y. Ishii M. Iwata N. Watanabe N. Uehara M. Yasujima Nationwide surveillance of parenteral antibiotics containing meropenem activities against clinically isolated strains in 2004 Jpn J Antibiot 58 2005 655 689
18. T. Kondo K. Yoshida S. Tanayama Metabolic fate of cefozopran hydrochloride, a new broad-spectrum cephalosporin, in rats and dogs Jpn J Chemother 41 1993 81 95
19. J.W. Mouton M.N. Dudley O. Cars H. Derendorf G.L. Drusano Standardization of pharmacokinetic/pharmacodynamic (PK/PD) terminology for anti-infective drugs: an update J Antimicrob Chemother 55 2005 601 607 10.1093/jac/dki079
20. R.E. Ariano A. Nyhlén J.P. Donnelly D.S. Sitar G.K. Harding S.A. Zelenitsky Pharmacokinetics and pharmacodynamics of meropenem in febrile neutropenic patients with bacteremia Ann Pharmacother 39 2005 32 38
21. T. Takenaka T. Watanabe T. Hayashi K. Hata N. Ono H. Kumon Pharmacokinetics and dosage planning of cefozopran in patients with renal insufficiency Jpn J Chemother 41 1993 147 153
22. Y. Kanimoto M. Takahashi S. Gouhara K. Okada Pharmacokinetics of cefozopran in the aged patients Jpn J Chemother 41 1993 154 157
23. Y. Sakurai T. Hishikawa N. Hiramatsu Y. Sagara M. Kuwahara M. Nagasaki Pharmacokinetic analysis of cefozopran in neonatal infections – population pharmacokinetics using NONMEM Jpn J Antibiot 52 1999 16 23
24. C. Li J.L. Kuti C.H. Nightingale D.P. Nicolau Population pharmacokinetic analysis and dosing regimen optimization of meropenem in adult patients J Clin Pharmacol 46 2006 1171 1178 10.1177/0091270006291035
25. S.M. Bhavnani J.P. Hammel B.B. Cirincione M.A. Wikler P.G. Ambrose Use of pharmacokinetic-pharmacodynamic target attainment analyses to support phase 2 and 3 dosing strategies for doripenem Antimicrob Agents Chemother 49 2005 3944 3947 10.1128/AAC.49.9.3944-3947.2005